ALZpath is a life sciences. Over the past three years, ALZpath has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Antibodies
Focus Area
Neurology
Licensing, acquisition, and partnership transactions involving ALZpath in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| pTau217 antibody | Alamar Biosciences | Antibodies | Discovery | license | Jul 23, 2026 |
Therapeutic areas and modalities where ALZpath is most active based on deal history and clinical trial data.
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
ALZpath is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, ALZpath ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for ALZpath include Neurology (2 deals and trials). In terms of modality, ALZpath has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for ALZpath and 700+ other biopharma companies. Use our Solidus to benchmark your asset against ALZpath's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.